Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study

PURPOSE: In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival (PFS) as initial treatment of estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer. We assessed the benefit of palbociclib plus letrozole in Asians. PATIEN...

Descripción completa

Detalles Bibliográficos
Autores principales: Im, Seock-Ah, Mukai, Hirofumi, Park, In Hae, Masuda, Norikazu, Shimizu, Chikako, Kim, Sung-Bae, Im, Young-Hyuck, Ohtani, Shoichiro, Huang Bartlett, Cynthia, Lu, Dongrui R., Iyer, Shrividya, Mori, Yuko, Mori, Ave, Gauthier, Eric, Finn, Richard S., Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
ORIGINAL REPORT
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550032/
https://www.ncbi.nlm.nih.gov/pubmed/31125276
http://dx.doi.org/10.1200/JGO.18.00173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550032/
https://www.ncbi.nlm.nih.gov/pubmed/31125276
http://dx.doi.org/10.1200/JGO.18.00173

Ejemplares similares